These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26764045)

  • 61. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
    J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
    Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ
    Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Retrospective study comparing low-dose versus standard dose of bortezomib in patients with multiple myeloma].
    Espinoza Zelada M; Befferman Cordova N; Ocqueteau Tachini M; Ramírez Villanueva P; Galleguillos M M; Sarmiento Maldonado M
    Medwave; 2015 Mar; 15(2):e6098. PubMed ID: 25831273
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
    Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
    Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving borte- zomib-based therapy for multiple myeloma.
    Zhou X; Wang J; Xia J; Cheng F; Mao J; Zhu J; Guo H
    Cancer Biomark; 2018; 22(1):43-48. PubMed ID: 29562497
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease].
    Solovyev MV; Mendeleeva LP; Pokrovskaya OS; Nareyko MV; Firsova MV; Galtseva IV; Davydova YO; Kapranov NM; Kuzmina LA; Gemdzhian EG; Savchenko VG
    Ter Arkh; 2017; 89(7):25-31. PubMed ID: 28766537
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.
    García-Sanz R; González-Porras JR; Hernández JM; Polo-Zarzuela M; Sureda A; Barrenetxea C; Palomera L; López R; Grande-García C; Alegre A; Vargas-Pabón M; Gutiérrez ON; Rodríguez JA; San Miguel JF
    Leukemia; 2004 Apr; 18(4):856-63. PubMed ID: 14973508
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil.
    Vigolo S; Zuckermann J; Bittencourt RI; Silla L; Pilger DA
    Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):135-142. PubMed ID: 28636891
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effective response with bortezomib retreatment in relapsed multiple myeloma--a multicentre retrospective survey in Switzerland.
    Taverna C; Voegeli J; Trojan A; Olie RA; von Rohr A
    Swiss Med Wkly; 2012; 142():w13562. PubMed ID: 22544478
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
    Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
    J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial.
    Dytfeld D; Griffith KA; Friedman J; Lebovic D; Harvey C; Kaminski MS; Jakubowiak AJ
    Leuk Lymphoma; 2011 Jul; 52(7):1271-80. PubMed ID: 21699382
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The role of complete response in multiple myeloma.
    Harousseau JL; Attal M; Avet-Loiseau H
    Blood; 2009 Oct; 114(15):3139-46. PubMed ID: 19638622
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
    Hoering A; Crowley J; Shaughnessy JD; Hollmig K; Alsayed Y; Szymonifka J; Waheed S; Nair B; van Rhee F; Anaissie E; Barlogie B
    Blood; 2009 Aug; 114(7):1299-305. PubMed ID: 19515721
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Impact of Extended Treatment Interval on the Prognosis of Multiple Myeloma Patients: A Retrospective Study.
    Sun C; Ye JN; Mao JJ; Ma KW; Zhou X
    Oncol Res Treat; 2020; 43(11):592-604. PubMed ID: 33045715
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy.
    Clark CA; Mosse CA; Chen H; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Kassim AA; Savani BN; Sengsayadeth S; Jagasia M; Cornell RF
    Bone Marrow Transplant; 2018 Dec; 53(12):1589-1592. PubMed ID: 29915217
    [No Abstract]   [Full Text] [Related]  

  • 78. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era.
    Okura M; Ida N; Yamauchi T
    Med Oncol; 2020 Oct; 37(11):103. PubMed ID: 33068194
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients.
    Bladé J; López-Guillermo A; Bosch F; Cervantes F; Reverter JC; Montserrat E; Rozman C
    Br J Haematol; 1994 Sep; 88(1):117-21. PubMed ID: 7803233
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Multiple myeloma: Current advances and future directions.
    Ola Landgren C
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101155. PubMed ID: 32139007
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.